<DOC>
	<DOCNO>NCT01922050</DOCNO>
	<brief_summary>Part 1 : To identify Maximum Tolerated Dose ( MTD ) level two formulation LEO 43204 daily treatment two consecutive day Part 2 : To evaluate efficacy two formulation LEO 43204 two dos daily treatment two consecutive day compare vehicle formulation</brief_summary>
	<brief_title>A Study Increasing Strengths , Safety Efficacy Two Formulas LEO 43204 Face Chest Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Following verbal write information trial , subject must provide informed consent document signing Informed Consent Form ( ICF ) prior trialrelated procedure . 2 . Part 1 : Subjects 5 20 clinically typical , visible discrete AKs face 3 . Part 2 : Subjects 5 20 clinically typical , visible discrete AKs either face within contiguous area approximately 250 cm2 ( 40 in2 ) chest 4 . Subject least 18 year age . 5 . Female subject must either : 1 . Nonchildbearing potential , i.e. , confirmed clinical history sterility ( e.g. , subject without uterus tubal ligation ) , , 2 . Childbearing potential , provide confirm negative urine pregnancy test prior trial treatment . 6 . Female subject childbearing potential must use effective contraception throughout study . 1 . Location treatment area within 5 cm ( 2 inch ) : 1. incompletely heal wound , 2. suspect basal squamous cell carcinoma . 2 . Prior treatment ingenol mebutate gel treatment area . 3 . Lesions treatment area : 1. atypical clinical appearance ( e.g. , hypertrophic , hyperkeratotic cutaneous horn ) and/or 2. recalcitrant disease ( e.g. , respond cryotherapy two previous occasion ) . 4 . History evidence skin condition trial indication would interfere evaluation trial medication ( e.g. , eczema , unstable psoriasis , xeroderma pigmentosum , Rosacea ) , investigator 's discretion . 5 . Use cosmetic therapeutic product procedure could interfere assessment treatment area . 6 . Any disease medical condition history presence cancer , cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunological , neurological disease disorder , , opinion investigator , make subject unsuitable participate trial . 7 . Any abnormal laboratory ECG finding clinically significant would impact safety subject interpretation study result , determine investigator . 8 . Anticipated need hospitalisation outpatient surgery first 15 day first trial medication application . Note cosmetic/therapeutic procedure exclude fall outside criterion detail Prohibited Therapies Medications . 9 . Known sensitivity allergy ingredient LEO 43204 . 10 . Presence acute sunburn within treatment area . 11 . Current enrolment participation investigational clinical trial within 30 day entry trial . 12 . Subjects previously randomise trial ( Part 1 2 ) . 13 . Female subject breastfeed . 14 . In opinion investigator , subject unlikely comply Clinical Study Protocol ( e.g. , alcoholism , drug dependency psychotic state ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>